Novartis’ takeover-driven dystrophy asset gained momentum after the Swiss drugmaker posted phase 1/2 success tied to regulatory discussions for its dystrophy program from the Avidity Biosciences acquisition. The update sets the stage for engagement with global regulators on what comes next for the asset, positioning it as a key component of Novartis’ rare disease strategy. In CML, Enliven Therapeutics disclosed updated early-phase results for ELVN-001 in its Enable trial. The company reported that the major molecular response in the proposed 80 mg go-forward cohort increased to 48% versus a previously reported 38%, supporting plans for a phase 3 program later this year.